Friday, 01 July, 2022

What should you know about the Misoprostol tablet?


Misoprostol is an efficient cervical ripening medication that may be used before surgical abortion in the first trimester. It is particularly advised for women between the ages of 12 and 14 weeks of pregnancy, adolescents, and those in whom cervical dilation is likely to be problematic owing to patient circumstances or inexperienced providers. Misoprostol tablet is prescribed to patients who are using nonsteroidal anti-inflammatory medicines (NSAIDs), such as aspirin, to reduce their risk of developing stomach ulcers.

How is it consumed

A synthetic prostaglandin analogue, misoprostol is available as an oral preparation for the prevention and treatment of gastroduodenal damage caused by nonsteroidal anti-inflammatory medications (NSAIDs) (NSAIDs). The drug is, however, used off-label in the practice of obstetrics and gynaecology for a variety of indications, including medication abortion, medical management of miscarriage, induction of labour (including cervical ripening before surgical procedures), and the treatment of postpartum haemorrhage (including uterine rupture).

Misoprostol tablet side effects are dosage-dependent and include cervical softening and dilation, uterine contractions, nausea, vomiting, diarrhoea, fever, and chills. Misoprostol is used to treat miscarriage and to prevent pregnancy. 1 Although misoprostol is not authorised by the United States Food and Drug Administration (FDA) for these uses, the FDA removed pregnancy from the label indicating that it is no longer an absolute contraindication to misoprostol usage.

Misoprostol has many benefits over other synthetic prostaglandin analogues, including its inexpensive cost, extended shelf life, lack of requirement for refrigeration, and availability around the globe. It also helps to avoid pregnancy when used in conjunction with other contraceptives.

 

The birth defects

Misoprostol is a teratogen, which means it causes birth defects. Among the congenital defects associated with misoprostol exposure during early pregnancy are skull defects, bladder hypertrophy, arthrogryposis, cranial nerve palsies, facial malformations, terminal transverse limb defects, and Moebius sequence. Misoprostol exposure during early pregnancy is also associated with the Moebius sequence.

Misoprostol-induced uterine contractions are likely to be the cause of this constellation of congenital abnormalities, which is thought to be produced by a vascular disturbance. When population registries have been analysed, the occurrence of these anomalies does not seem to be very high, which is particularly surprising considering that misoprostol exposure is fairly widespread among specific patient groups.

misoprostol offers the effectiveness and decreased side effects of vaginal administration combined with high acceptability for both patients and staff. When compared to a placebo, these regimens dramatically enhance baseline cervical dilatation and make it easier to achieve additional mechanical dilation.